Julia Maria Ressler

Dr. Julia Maria Ressler

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2021 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
JRJulia Maria Ressler
Julia Maria Ressler
MKMatthias Karasek
Matthias Karasek
LKLukas Koch
Lukas Koch
RSRita Silmbrod
Rita Silmbrod
JMJoanna Mangana
Joanna Mangana
CHChristoph Hoeller
Christoph Hoeller
Background Talimogene laherparepvec (T-VEC) is a licensed therapy for use in melanoma patients of stage IIIB-IVM1a with injectable, unresectable metastatic lesions in Europe. Approval was based on the Oncovex Pivotal Trial in Melanoma study, which also included patients with distant metastases and demonstrated an overall response rate (ORR) of 40.5% and a complete response (CR) rate of 16.6%. Objectives The aim of this study was to assess the outcome of melanoma patients treated with T-VEC in a real-life clinical setting. Methods Based on data from 10 melanoma centers in Austria, Switzerland and southern Germany, we conducted a retrospective chart review, which included 88 patients (44 male, 44 female) with a median age of 72 years (range 36–95 years) treated with T-VEC during the period from May 2016 to January 2020. Results 88 patients fulfilled the inclusion criteria for analysis. The ORR was 63.7%. 38 patients (43.2%) showed a CR, 18 (20.5%) had a partial response, 8 (9.1%) had stable disease and 24 (27.3%) patients had a progressive disease. The median treatment period was 19 weeks (range: 1–65), an average of 11 doses (range: 1–36) were applied. 39 (45.3%) patients developed adverse events, mostly mild, grade I (64.1%). Conclusion This real-life cohort treatment with T-VEC showed a high ORR and a large number of durable CRs.

12 December 2022 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
KSKatharina Schumann
Katharina Schumann
CMCornelia Mauch
Cornelia Mauch
KKKai‐Christian Klespe
Kai‐Christian Klespe
CLCarmen Loquai
Carmen Loquai
UNUlrike Nikfarjam
Ulrike Nikfarjam
CPChristian Posch
Christian Posch
Background: Programmed death‐1 (PD‐1) antibodies and BRAF + MEK inhibitors are widely used for adjuvant therapy of fully resected high‐risk melanoma. Little is known about treatment efficacy outside of phase III trials. This real‐world study reports on clinical outcomes of modern adjuvant melanoma treatment in specialized skin cancer centers in Germany, Austria and Switzerland.Methods: Multicenter, retrospective study investigating stage III–IV melanoma patients receiving adjuvant nivolumab (NIV), pembrolizumab (PEM) or dabrafenib + trametinib (D + T) between 1/2017 and 10/2021. The primary endpoint was 12‐month recurrence‐free survival (RFS). Further analyses included descriptive and correlative statistics, and a multivariate linear‐regression machine learning model to assess the risk of early melanoma recurrence.Results: In total, 1198 patients from 39 skin cancer centers from Germany, Austria and Switzerland were analysed. The vast majority received anti PD‐1 therapies (n = 1003). Twelve‐month RFS for anti PD‐1 and BRAF + MEK inhibitor‐treated patients were 78.1% and 86.5%, respectively (hazard ratio [HR] 1.998 [95% CI 1.335–2.991]; p = 0.001). There was no statistically significant difference in overall survival (OS) in anti PD‐1 (95.8%) and BRAF + MEK inhibitor (96.9%) treated patients (p > 0.05) during the median follow‐up of 17 months. Data indicates that anti PD‐1 treated patients who develop immune‐related adverse events (irAEs) have lower recurrence rates compared to patients with no irAEs (HR 0.578 [95% CI 0.443–0.754], p = 0.001). BRAF mutation status did not affect overall efficacy of anti PD‐1 treatment (p > 0.05). In both, anti PD‐1 and BRAF + MEK inhibitor treated cohorts, data did not show any difference in 12‐month RFS and 12‐month OS comparing patients receiving total lymph node dissection (TLND) versus sentinel lymph node biopsy only (p > 0.05). The recurrence prediction model reached high specificity but only low sensitivity with an AUC = 0.65. No new safety signals were detected. Overall, recorded numbers and severity of adverse events were lower than reported in pivotal phase III trials.Conclusions: Despite recent advances in adjuvant melanoma treatment, early recurrence remains a significant clinical challenge. This study shows that TLND does not reduce the risk of early melanoma recurrence and should only be considered in selected patients. Data further highlight that variables collected during clinical routine are unlikely to allow for a clinically relevant prediction of individual recurrence risk.

18 February 2019 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
JRJulia Maria Ressler
Julia Maria Ressler
RSR. Silmbrod
R. Silmbrod
ASA. Stepan
A. Stepan
FTF. Tuchmann
F. Tuchmann
ACA. Cicha
A. Cicha
CHC. Hoeller
C. Hoeller
Talimogene laherparepvec (T‐VEC) is a intralesional oncolytic virotherapy, licensed in the European Union (EU) for locoregional advanced melanoma of American Joint Committee on Cancer (AJCC) stages IIIB, IIIC and IVM1a. Organ transplant recipients (OTRs) are so far excluded from all clinical trials dealing with immunotherapies due to the risk of transplant rejection. A 58‐year‐old caucasian male with a history of a heart and kidney transplantation in 2014 was diagnosed with melanoma (Breslow thickness of 1.6 mm, pT2a) on the left arm in September 2015. In March 2016, he developed in transit metastases and a local therapy with a combination of topical imiquimod (5%) and cryotherapy of individual lesions was initiated. However, in November 2016 therapy was stopped following a local progression of the metastases. An interdisciplinary decision to treat the patient with T‐VEC was taken. After 11 cycles of T‐VEC, the patient showed a complete response. As of June 2018, 11 months after the last treatment cycle of T‐VEC, the patient continues to be tumor‐free. The patient tolerated the therapy well with only mild adverse events and did not show any sign of graft rejection or loss of function of the transplanted organs. We conclude that T‐VEC can be a potential effective and safe treatment in patients with a history of organ transplantation. Nevertheless, due to this special situation, the risks and benefits should always be discussed in an interdisciplinary tumor board.

10 May 2023 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
JLJean-Matthieu L'Orphelin
Jean-Matthieu L'Orphelin
JCJ. Cassecuel
J. Cassecuel
LKL. Kandolf
L. Kandolf
CHC. A. Harwood
C. A. Harwood
PTP. Tookey
P. Tookey
EDEuropean Association of Dermato‐Oncology
European Association of Dermato‐Oncology
Background: Checkpoint inhibitors provide an effective approach for the melanoma treatment. They prolong lymphocyte effects, which explains the cytotoxicity underlying immune‐related adverse events (IrAEs). Cutaneous IrAEs affect nearly 40% of PD‐1i and 50% of CTLA4i‐treated patients. Severe cutaneous irAE do not often occur but could be life‐threatening and may persist despite treatment discontinuation.Methods: We aimed to investigate cutaneous IrAEs in a cohort of patients treated with ICI across Europe in an effort to characterize the reactions in a real‐world, phase IV, post‐marketing study using a follow‐up questionnaire.Data since November 2016 until March 2021 were obtained from the Melskintox database, a European multicentric biobank dedicated to the follow‐up of melanoma and cutaneous adverse events, supported by EADO. The dermatoses reported were pooled into four categories: inflammatory dermatosis, bullous diseases, drug‐related eruptions and pigmentary diseases.Results: Inflammatory benign dermatoses (n = 63) represented the most common group of reactions (52.5%), followed by drug‐related eruptions (n = 24, 20%), pigmentary diseases (n = 23, 19.2%) and bullous diseases (n = 10, 8.3%). Grade II (n = 41, 34.2%) are represented by bullous pemphigoid, eczema, hypodermitis, lichenoid eruption, maculopapular rash, pruritus, psoriasis‐like rash, urticarial eruption and vitiligo. Grade III (n = 18, 15.0%) are represented by bullous pemphigoid, lichenoid eruption and rashes. Grade IV (n = 2, 1.7%) is only represented by bullous disease. Most cutaneous IrAEs led to immunotherapy continuation (n = 95, 88.0%). CR is associated with more severe the cutaneous irAEs. We report an average time‐to‐onset of 208 days and some late‐onset events.Conclusion: Our study has characterized the clinical spectrum of cutaneous irAEs, their timing and severity and their relationship with tumour response. Grade I–II cutaneous IrAE are easily managed allowing ongoing anticancer treatment. Severe late‐onset cutaneous irAE are not uncommon. A dermatological follow‐up helps mitigate the risk of life‐threatening adverse events. These findings highlight the importance of oncodermatological involvement in management of patients with melanoma receiving immunotherapy.

16 January 2025 in Nature Cancer
Verified
Journal Article
Open access
PDF file
JRJulia Maria Ressler
Julia Maria Ressler
MPMaud Plaschka
Maud Plaschka
RSRita Silmbrod
Rita Silmbrod
VBVictoria Bachmayr
Victoria Bachmayr
LSLisa Ellen Shaw
Lisa Ellen Shaw
CHChristoph Hoeller
Christoph Hoeller
We present a single-arm, phase II, neoadjuvant trial with the oncolytic virus talimogene laherparepvec (T-VEC) in 18 patients with difficult-to-resect cutaneous basal cell carcinomas. The primary end point, defined as the proportion of patients, who after six cycles of T-VEC (13 weeks), become resectable without the need for plastic reconstructive surgery, was already achieved after stage I (9 of 18 patients; 50.0%); thus the study was discontinued for early success. The objective response rate was 55.6% and the complete pathological response rate was 33.3%. Secondary end points included safety, relapse-free survival and overall survival, time to occurrence of new basal cell carcinomas and biological read outs. Only mild adverse events occurred. The 6-month relapse-free survival and overall survival rates were 100%. In two patients a new basal cell carcinoma was diagnosed. T-VEC led to a significant increase in cytotoxic T cells (P = 0.0092), B cells (P = 0.0004) and myeloid cells (P = 0.0042) and a decrease in regulatory T cells (P = 0.0290) within the tumor microenvironment. Together, neoadjuvant T-VEC represents a viable treatment option for patients with difficult-to-resect basal cell carcinomas (EudraCT no. 2018-002165-19).

21 January 2024 in European Journal of Cancer
Verified
Journal Article
Closed access
ATAmelia M. Taylor
Amelia M. Taylor
JMJanet McKeown
Janet McKeown
FDFlorentia Dimitriou
Florentia Dimitriou
SJSarah K. Jacques
Sarah K. Jacques
LZLisa Zimmer
Lisa Zimmer
AMAlexander M. Menzies
Alexander M. Menzies